<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02526615</url>
  </required_header>
  <id_info>
    <org_study_id>TurkuUH-ROSI</org_study_id>
    <nct_id>NCT02526615</nct_id>
  </id_info>
  <brief_title>Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes</brief_title>
  <acronym>ROSI</acronym>
  <official_title>Comparison of Effects of Rosiglitazone and Metformin on Myocardial, Skeletal Muscle, Liver and Adipose Tissue Insulin Stimulated Glucose Uptake in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SmithKline Beecham</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to compare the effects of rosiglitazone and metformin on&#xD;
      insulin stimulated glucose uptake in subjects with type 2 diabetes. Whole body, and skeletal&#xD;
      muscle, heart and adipose tissue insulin stimulated glucose uptake is measured during&#xD;
      euglycemic hyperinsulinemic clamp and positron-emission tomography scanning before and 26&#xD;
      weeks after treatment in 48 newly diagnosed subjects with type 2 diabetes. Subjects will be&#xD;
      randomized to receive either rosiglitazone or metformin or placebo, according to a simple&#xD;
      randomization procedure with double blinding.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin resistance is a pivotal underlying metabolic abnormality in most subjects with type 2&#xD;
      diabetes. Clinical experience has proved metformin to be efficacious treatment in patients&#xD;
      with type 2 diabetes. Rosiglitazone is a novel antidiabetic agent, which has been shown to&#xD;
      decrease fasting plasma glucose concentrations in animal models and in clinical trials. There&#xD;
      are no previous studies that compare the effects of rosiglitazone and metformin on insulin&#xD;
      stimulated glucose uptake in subjects with type 2 diabetic in different organs.&#xD;
&#xD;
      PET is very sensitive in detecting changes in glucose uptake and blood flow and, is the&#xD;
      method of choice to investigate the effects of medical interventions. Due to sensitivity of&#xD;
      these functional parameters only moderate or small number of subjects need to be studied.&#xD;
      This makes it feasible to perform tightly controlled intervention studies in a very&#xD;
      cost-effective way.&#xD;
&#xD;
      The objectives of this study are to compare the effects of rosiglitazone and metformin on&#xD;
      insulin stimulated glucose uptake in subjects with type 2 diabetes. PET measurements on&#xD;
      myocardium, skeletal muscle and subcutaneous and visceral fat are performed at baseline and&#xD;
      at the end of the treatment period. Furthermore, the effect of exercise on skeletal muscle&#xD;
      blood flow and glucose uptake is studied.&#xD;
&#xD;
      The study consists of 48 newly diagnosed subjects with type 2 diabetes. Subjects will be&#xD;
      randomized to receive either rosiglitazone or metformin or placebo, according to a simple&#xD;
      randomization procedure with double blinding. The investigators will also study ten&#xD;
      age-matched non-diabetic control subjects, who will undergo the same PET study procedure as&#xD;
      subjects with type 2 diabetes.&#xD;
&#xD;
      A study of the effects of antidiabetic oral medication in newly diagnosed subjects with type&#xD;
      2 diabetes is of great importance for the understanding of the differences in mode of action&#xD;
      of the different antidiabetic drugs. Such a study would contribute to elucidate advantages&#xD;
      and disadvantages with certain drugs and potential additive effects in combination therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">December 2001</completion_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity in skeletal muscle</measure>
    <time_frame>26 weeks</time_frame>
    <description>pre and at 26 weeks measured with euglycemic clamp and 18-F-2-fluoro-2-deoxy-D-glucose scanning skeletal muscle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>skeletal muscle blood flow</measure>
    <time_frame>26 weeks</time_frame>
    <description>measured using PET scanning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin signaling pathways in skeletal muscle</measure>
    <time_frame>26 weeks</time_frame>
    <description>measured from muscle biopsies taken before and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin sensitivity of bone marrow fat</measure>
    <time_frame>26 weeks</time_frame>
    <description>measured using PET images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin stimulated intestinal glucose uptake</measure>
    <time_frame>26 weeks</time_frame>
    <description>measured using PET images</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Insulin Sensitivity</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, 2 tablets per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500mg 1 tablet 2 times per day for the first 2 weeks, then after that 2 tables 2 times per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosiglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 mg 1 tablets 2 times per day for the first 2 weeks, then after that 2 tablets 2 times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>Patients received either placebo, metformin or rosiglitazone</description>
    <arm_group_label>Rosiglitazone</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Patients received either placebo, metformin or rosiglitazone</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients received either placebo, metformin or rosiglitazone</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 40-75 years,&#xD;
&#xD;
          -  BMI 25-35 kg/m2,&#xD;
&#xD;
          -  WHO criteria for type 2 diabetes fasting plasma glucose&gt;=7.0 mmol/l on at least 2&#xD;
             separate occasions,&#xD;
&#xD;
          -  C-peptide&gt;0.2 nmol/l&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  plasma glucose &lt; 6.1 or &gt;10 mmol/l after the screening period&#xD;
&#xD;
          -  cardiac heart failure&#xD;
&#xD;
          -  diagnosed coronary heart disease&#xD;
&#xD;
          -  severe aortic, mitral or tricuspidal valve disease&#xD;
&#xD;
          -  blood pressure &gt; 160/ 100 mg Hg&#xD;
&#xD;
          -  any previous or present hepatic (GT &gt;100, alanine amino transferase &gt;3 x upper limit&#xD;
             of the reference range) or renal (S-creatinine &gt; 130) disease&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  proliferative retinopathy&#xD;
&#xD;
          -  microalbuminuria&#xD;
&#xD;
          -  subjects with history of lactate acidosis&#xD;
&#xD;
          -  symptomatic polyneuropathy&#xD;
&#xD;
          -  antidiabetic medication&#xD;
&#xD;
          -  changes in antihypertensive medication or beta-blockers in medication&#xD;
&#xD;
          -  metal objects in region of imaging&#xD;
&#xD;
          -  anemia with Hb &lt; 100 in mean or &lt; 90 in women&#xD;
&#xD;
          -  oral corticosteroid treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pirjo Nuutila, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turku PET Centre</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku university hospital, PET center</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku PET Centre (Turku University Hospital)</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>August 11, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rosiglitazone</keyword>
  <keyword>metformin</keyword>
  <keyword>muscle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

